flâneur

Why fixing the IRA matters to all of us — RApport

rapport.bio · 818 words · saved by 1 readers

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively. By Peter Kolchinsky & Peter Thompson Peter Kolchinsky is founder and Managing Partner at RA Capital Management. Peter Thompson is a General Partner at OrbiMed Advisors. RA Capital’s Peter Kolchinsky and OrbiMed’s Peter Thompson joined their voices to underscore the magnitude of the Inflation Reduction Act’s (IRA’s) impact on the economics of drug development, especially for age-related diseases. Bottom line: Unless our industry unites to call on Congress to fix the IRA’s discrepancy in market-based pricing periods before CMS steps in (nine years for small molecules vs. thirteen years for biologics), otherwise-investable programs will no longer merit investors’ backing and overall funding for innovative small molecule programs will likely undergo a significant decline. Read the full letter at No Patient Left Behind. And if you agree, plea

Why fixing the IRA matters to all of us Policy Biotech Mar 23 Written By Guest User By Peter Kolchinsky & Peter Thompson Peter Kolchinsky is founder and Managing Partner at RA Capital Management. Peter Thompson is a General Partner at OrbiMed Advisors. Tweet March 23, 2023 RA Capital’s Peter Kolchinsky and OrbiMed’s Peter Thompson joined their voices to underscore the magnitude of the Inflation Reduction Act’s (IRA’s) impact on the economics of drug development, especially for age-related diseases. Bottom line: Unless our industry unites to call on Congress to fix the IRA’s discrepancy in mark

saved by

related reading